Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii

Authors:

Abstract
The aim of this multi-hospital study was to assess the in vitro activity of doripenem and its comparators, imipenem and meropenem, using the new CLSI breakpoints against a large population of a frequently isolated nosocomial pathogen, Acinetobacter baumannii. During a 2-year period, four referral or tertiary hospitals submitted 400 isolates of A. baumannii for susceptibility testing using imipenem, meropenem, and doripenem via disk diffusion and E-test methods. A subset of 390 isolates was resistant to all three tested carbapenems. Doripenem and meropenem (MIC50, 32 μg ml-1) had comparable activity, albeit doripenem's activity was greater than imipenem (MIC50, >32 μg ml-1). A significantly higher proportion of the isolates were inhibited by doripenem than by imipenem at MIC values of 12, 16, 24 and 32 μg ml-1 (Pin vitro activity than imipenem in terms of zone breakpoints and MIC values, but its activity is comparable to meropenem. Doripenem should be considered as a therapeutic option for monotherapy or combination therapy, particularly when the therapeutic options are limited.
Funding Information
  • Tehran University of Medical Sciences and Health Services (90-02-27-13796)
  • Academy of Sciences for the Developing World (11-119 RG/PHA/AS_C-UNESCO FR: 3240262646)

This publication has 24 references indexed in Scilit: